€35.00
0.29% yesterday
Xetra, Sep 27, 05:35 pm CET
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Sector
Industry

Dermapharm Stock price

€35.00
+1.00 2.94% 1M
+0.84 2.46% 6M
-7.34 17.34% YTD
-3.78 9.75% 1Y
-50.85 59.23% 3Y
-0.26 0.74% 5Y
+9.00 34.62% 10Y
Xetra, Closing price Fri, Sep 27 2024
+0.10 0.29%
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Sector
Industry

Key metrics

Market capitalization €1.88b
Enterprise Value €2.80b
P/E (TTM) P/E ratio 22.63
EV/FCF (TTM) EV/FCF 27.82
EV/Sales (TTM) EV/Sales 2.47
P/S ratio (TTM) P/S ratio 1.66
P/B ratio (TTM) P/B ratio 3.41
Dividend yield 2.52%
Last dividend (FY23) €0.88
Revenue growth (TTM) Revenue growth -0.35%
Revenue (TTM) Revenue €1.13b
EBIT (operating result TTM) EBIT €196.03m
Free Cash Flow (TTM) Free Cash Flow €100.52m
Cash position €165.76m
EPS (TTM) EPS €1.54
P/E forward 18.22
P/S forward 1.58
EV/Sales forward 2.36
Show more

Is Dermapharm a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Dermapharm Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Dermapharm forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Dermapharm forecast:

Buy
100%

Financial data from Dermapharm

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1,132 1,132
0% 0%
100%
- Direct Costs 778 778
7% 7%
69%
354 354
14% 14%
31%
- Selling and Administrative Expenses 59 59
456% 456%
5%
- Research and Development Expense - -
-
-
295 295
26% 26%
26%
- Depreciation and Amortization 99 99
0% 0%
9%
EBIT (Operating Income) EBIT 196 196
35% 35%
17%
Net Profit 83 83
32% 32%
7%

In millions EUR.

Don't miss a Thing! We will send you all news about Dermapharm directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dermapharm Stock News

EQS
about one month ago
Grünwald, 27. August 2024 – Die Dermapharm Holding SE („Dermapharm“), ein innovativer und wachstumsstarker Hersteller von Markenarzneimitteln und anderen Gesundheitsprodukten, veröffentlicht heute den prüferisch durchgesehenen Halbjahresfinanzbericht für das laufende Geschäftsjahr 2024 und bestä...
EQS
about one month ago
Grünwald, 14. August 2024 – Die Dermapharm Holding SE („Dermapharm“), ein innovativer und wachstumsstarker Hersteller von Markenarzneimitteln und anderen Gesundheitsprodukten, veröffentlicht heute ihre ungeprüften vorläufigen IFRS-Konzern-Geschäftszahlen für das erste Halbjahr 2024. Das starke Wa...
EQS
3 months ago
Dermapharm vertreibt im Segment „Markenarzneimittel“ mehr als 1.300 Arzneimittelzulassungen mit über 400 pharmazeutischen Wirkstoffen. Das Sortiment von Arzneimitteln ist auf ausgewählte Therapiegebiete spezialisiert, in denen Dermapharm vor allem in Deutschland eine führende Marktposition besetz...
More Dermapharm News

Company Profile

Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.

Head office Germany
CEO Hans-Georg Feldmeier
Founded 1991
Website www.dermapharm.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today